A multimerized form of recombinant human CD40 ligand supports long-term activation and proliferation of B cells

Cytotherapy

Volumn 16, Issue 11, 2014, Pages 1537-1544

  Garcia Marquez, Maria A ^a   Shimabukuro Vornhagen, Alexander ^a   Theurich, Sebastian ^a,b,c   Kochanek, Matthias ^a   Weber, Tanja ^a   Wennhold, Kerstin ^a   Dauben, Alexandra ^d   Dzionek, Andrzej ^d   Reinhard, Claudia ^d   von Bergwelt Baildon, Michael ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^d MILTENYI BIOTEC GMBH   (Germany)

Author keywords

Antigen presentation; APC; B cells; CD40L; Immunotherapy; Proliferation

Indexed keywords

CD19 ANTIGEN; CD40 LIGAND;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIVISION; CELL EXPANSION; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; FEEDER CELL; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; MONOLAYER CULTURE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; UPREGULATION; 3T3 CELL LINE; ANIMAL; CYTOLOGY; GENETIC TRANSFECTION; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; T LYMPHOCYTE;

ANIMALS; ANTIGEN-PRESENTING CELLS; B-LYMPHOCYTES; CD40 LIGAND; CELL PROLIFERATION; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MICE; NIH 3T3 CELLS; T-LYMPHOCYTES; TRANSFECTION;

EID: 84912091270     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2014.05.011     Document Type: Article

References (29)

1. Kedar R., Sabag O., Licthenstein M., Lorberboum-Galski H. Soluble CD40 ligand (sCD40L) provides a new delivery system for targeted treatment: sCD40L-caspase 3 chimeric protein for treating B-cell malignancies. Cancer 2012, 18:6089-6104.
2. van Kooten C., Banchereau J. CD40-CD40 ligand. JLeukoc Biol 2000, 67:2-17.
3. Petersa A.L., Stunzb L.L., Bishopa G.A. CD40 and autoimmunity: the dark side of a great activator. Semin Immunol 2009, 21:293-300.
4. Schonbeck U., Mach F., Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 2000, 32:687-693.
5. Mazzei G.J., Edgerton M.D., Losberger C., Lecoanet-Henchoz S., Graber P., Durandy A., et al. Recombinant soluble trimeric CD40 ligand is biologically active. JBiol Chem 1995, 270:7025-7028.
6. Banchereau J., Bazan F., Blanchard D., Brière F., Galizzi J.P., van Kooten C., et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994, 12:881-922.
7. Ranheim E.A., Kipps T.J. Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. JExp Med 1993, 177:925-935.
8. von Bergwelt-Baildon M.S., Vonderheide R.H., Maecker B., Hirano N., Anderson K.S., Butler M.O., et al. Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood 2002, 99:3319-3325.
9. Yellin M.J., Sinning J., Covey L.R., Sherman W., Lee J.J., Glickman-Nir E., et al. Tlymphocyte T cell-B cell activation molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB1) and enhance their costimulatory activity. JImmunol 1994, 153:666-674.
10. Bretscher P.A. Atwo-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci U S A 1999, 96:185-190.
11. van Essen D., Kikutani H., Gray D. CD40 ligand-transduced co-stimulation of T cells in the development of helper function. Nature 1995, 378:620-623.
12. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997, 9:10-16.
13. Lapteva N., Seethammagari M.R., Hanks B.A., Jiang J., Levitt J.M., Slawin K.M., et al. Enhanced activation of human dendritic cells by inducible CD40 and toll-like receptor-4 ligation. Cancer Res 2007, 67:10528-10537.
14. Linch D.C., Devereux S. Monocyte- derived dendritic cells do not proliferate and are not susceptible to retroviral transduction. Br J Haematol 2000, 108:817-824.
15. Hackstein H., Morelli A.E., Thomson A.W. Designer dendritic cells for tolerance induction: guided not misguided missiles. Trends Immunol 2001, 22:437-442.
16. Barrat-Boyes D.M., Zimmer M.L., Harshyne L.A., Meyer E.M., Watkins S.C., Capuano S., et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. JImmunol 2000, 164:2487-2495.
17. Draube A., Klein-González N., Mattheus S., Brillant C., Hellmich M., Engert A., et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis. PLoS One 2011, 6:e18801.
18. Lenschow D.J., Sperling A.L., Cooke M.P., Freeman G., Rhee L., Decker D.C., et al. Differential up-regulation of the B7-1 and B7-2 costimulatory molecules after Ig receptor engagement by antigen. JImmunol 1994, 135:1990-1997.
19. Coughlin C.M., Vonderheide R.H. Targeting adult and pediatric cancers via cell-based vaccines and the prospect of activated B lymphocytes as a novel modality. Cancer Biol Ther 2003, 2:466-470.
20. Kondo E., Topp M.S., Kiem H.P., Obata Y., Morishima Y., Kuzushima K., et al. Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. JImmunol 2002, 169:2164-2171.
21. Banchereau J., de Paoli P., Valle A., Garcia E., Rousset F. Long-term human B cell lines dependent on interleukin and antibody to CD40. Science 1991, 251:70-72.
22. Banchereau J., Rousset F. Growing human B lymphocytes in the CD40 system. Nature 1991, 353:678-679.
23. Schultze J.L., Michalak S., Seamon M.J., Dranoff G., Jung K., Daley J., et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. JClin Invest 1997, 100:2757-2765.
24. Liebig T.M., Fiedler A., Zoghi S., Shimabukuro-Vornhagen A., von Bergwelt-Baildon M.S. Generation of Human CD40-activated B cells. J Vis Exp 2009, 1373.
25. Yoon S.H., Cho H.I., Kim T.G. Activation of B cells using Schneider 2 cells expressing CD40 ligand for the enhancement of antigen presentation in vitro. Exp Mol Med 2005, 37:567-574.
26. Schultze J.L., Cardoso A.A., Freeman G.J., Seamon M.J., Daley J., Pinkus G.S., et al. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity. Proc Natl Acad Sci US A 1995, 92:8200-8204.
27. Ivanov R., Aarts T., Hagenbeek A., Hol S., Ebeling S. B-cell expansion in the presence of the novel 293-CD40L-sCD40L cell line allows the generation of large numbers of efficient xenoantigen-free APC. Cytotherapy 2005, 7:62-73.
28. Kondo E., Gryschok L., Klein-Gonzalez N., Rademacher S., Weihrauch M.R., Liebig T., et al. CD40-activated B cells can be generated in high number and purity in cancer patients: analysis of immunogenicity and homing potential. Clin Exp Immunol 2008, 155:249-256.
29. Haswell L.E., Glennie M.J., Al-Shamkhani A. Analysis of the oligomeric requirement for signaling by CD40 using soluble multimeric forms of its ligand, CD154. Eur J Immunol 2001, 31:3094-3100.